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The hepatitis C virus (HCV) chronically infects 2% of the 
world population and effective treatment is limited by long 
duration and significant side-effects. Here, we describe a 
novel drug, intended as a “single-shot” therapy, which 
expresses three short hairpin RNAs (shRNAs) that simul-
taneously target multiple conserved regions of the HCV 
genome as confirmed in vitro by knockdown of an HCV 
replicon system. Using a recombinant adeno- associated 
virus (AAV) serotype 8 vector for delivery, comprehen-
sive transduction of hepatocytes was achieved in vivo in 
a nonhuman primate (NHP) model following a single 
intravenous injection. However, dose ranging studies per-
formed in 13 NHP resulted in high-expression levels of 
shRNA from wild-type (wt) Pol III promoters and dose-
 dependent hepatocellular toxicity, the first demonstration 
of shRNA-related toxicity in primates, establishing that the 
hepatotoxicity arises from highly conserved features of 
the RNA interference (RNAi) pathway. In the second gen-
eration drug, each promoter was re-engineered to reduce 
shRNA transcription to levels that circumvent toxicity but 
still inhibit replicon activity. In vivo testing of this modified 
construct in 18 NHPs showed conservation of hepatocyte 
transduction but complete elimination of hepatotoxicity, 
even with sustained shRNA expression for 50 days. These 
data support progression to a clinical study for treatment 
of HCV infection.
Received 24 December 2011; accepted 21 May 2012; advance online 
publication 26 June 2012. doi:10.1038/mt.2012.119
INTRODUCTION
Currently ~170 million people worldwide are chronically infected 
with the hepatitis C virus (HCV). HCV infects the human liver and 
the disease slowly progresses in chronically infected patients from 
an asymptomatic condition to end-stage liver cirrhosis in about one 
in four patients, at which time liver transplantation is required.1 he 
current prolonged treatment with interferon and ribavirin cures the 
disease in ~50% of patients and in combination with the new genera-
tion of protease inhibitors may result in an increased cure rate of up to 
75% in highly controlled clinical trials.2,3 However, the required treat-
ment duration remains prolonged (6–12 months) and oten results 
in signiicant side-efects. Because the HCV genome is comprised of 
a single RNA molecule and the intracellular portion of its infectious 
cycle occurs strictly within the cytoplasm, HCV is an ideal candi-
date for therapeutics based on RNA interference (RNAi). here have 
been numerous reports on the use of siRNAs and/or short hairpin 
RNAs (shRNAs) to inhibit HCV RNA replication in replicon model 
systems.4–7 Indeed, up to 80-fold decreases in HCV RNA levels have 
been observed, as well as the clearance of replicating HCV RNA in 
>98% of cells. Yet, because HCV is replicated with a self- encoded 
RNA-dependent RNA-Polymerase which lacks proof-reading activ-
ity, it is prone to mutant generation which can result in a loss of RNAi 
activity through the accumulation of nucleotide point mutations 
within the siRNA target sequence.8–10 To counteract the generation 
of escape mutants for HCV and other viruses, several groups have 
documented success using viral  vectors  capable of expressing mul-
tiple shRNA species against the viral genome targets.11–13
he initial optimism surrounding the development of shRNA 
therapeutics against human diseases has been tempered by reports 
suggesting that high levels of hairpin expression can cause toxicity 
in vivo. Grimm et al. were among the irst to demonstrate dose-
dependent shRNA-induced hepatocellular toxicity and death in 
murine models.14 his was followed by a number of other in vivo 
studies involving degeneration of murine striatal tissues15,16 or 
central nervous system neurons.17 It was hypothesized that liver 
damage was caused by high levels of expression of certain “toxic” 
shRNA sequences, resulting in a competition for cellular enzymes 
or pathways required to process endogenous miRNA species. To 
address this problem, diferent strategies have been employed by 
multiple groups to abrogate these toxic efects, including model-
ling the shRNA into the context of naturally occurring miRNA 
backbones16 or Alu-repeats,18 changing the type of viral vector 
used for delivery,17 or by using endogenous promoters that pos-
sess weak transcriptional activity.19–21
Correspondence: David A Suhy, Tacere Therapeutics, 5941 Optical Court, San Jose, California, USA. E-mail: dsuhy@tacerebio.com
Safe, Long-term Hepatic Expression of Anti-HCV 
shRNA in a Nonhuman Primate Model
David A Suhy1, Shih-Chu Kao1, Tin Mao1, Laurence Whiteley2, Hubert Denise3, 
Bernard Souberbielle3, Andrew D Burdick2, Kyle Hayes2, J Fraser Wright4,5, Helen Lavender3, 
Peter Roelvink1, Alexander Kolykhalov1, Kevin Brady3, Sterghios A Moschos3, Bernd Hauck4, 
Olga Zelenaia4, Shangzhen Zhou5, Curt Scribner1, Katherine A High4,6, Sara H Renison1 
and Romu Corbau3
1Tacere Therapeutics, San Jose, California, USA; 2Pfizer Global Research and Development, Drug Safety Research and Development, Cambridge, 
Massachusetts, USA; 3Pfizer Global Research & Development, Kent, UK; 4Division of Hematology and Center for Cellular and Molecular  Therapeutics, 
Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 5Department of Pathology and Laboratory Medicine, Children’s Hospital of 
 Philadelphia, and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 6Howard Hughes Medical Institute, 
 University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
MTOpen
© The American Society of Gene & Cell Therapy
Anti-HCV shRNA in a Nonhuman Primate Model
1738 www.moleculartherapy.org  vol. 20 no. 9 sep. 2012 
Direct modiication of the regulatory elements within the 
endogenous promoters to attenuate shRNA transcription and 
accumulation has not been previously described. All vertebrate 
small nuclear RNA type promoters like U6 are organized into 
a proximal region, containing the proximal sequence element 
(PSE), a distal region containing the enhancer, and a TATA box 
located between the PSE and the transcription initiation nucle-
otide; all three regions contribute signiicantly to binding of the 
transcription complex. Despite a high degree of sequence similar-
ity between the conserved elements of other Pol III promoters, 
exchanging the promoter-speciic PSE from U6-7 with analogous 
sequences in the U6-8 promoter signiicantly reduced transcrip-
tional activity as compared to the native promoter, demonstrating 
that these hybrid promoters have the potential to have reduced 
transcriptional activity.22
In this article, we describe an optimized therapeutic against 
HCV that expresses three shRNAs from a single vector. he 
simultaneous targeting of three highly conserved regions of the 
HCV viral genome substantially reduces the likelihood of escape 
mutants. A key to the success of this approach is an eicient deliv-
ery system that can transduce the majority of hepatocytes, thus 
eliminating all replicating virus in the HCV-infected cells and 
simultaneously providing prophylaxis to uninfected cells. Wild-
type (wt) adeno-associated virus (AAV) is a small, nonpatho-
genic, replication-incompetent virus that has been used in a wide 
variety of clinical studies. We used an AAV serotype 8 capsid 
which has been shown to transduce hepatocytes with a high 
level of eiciency in mouse models23,24 and in Rhesus macaques25 
and has also been used successfully in a recent clinical study for 
hemophilia B.26 Durability of transgene expression following AAV 
transduction of liver is robust, oten lasting years following a 
single injection.27 Furthermore, we used self-complementary vec-
tors, wherein the transgene expression cassette is packaged as a 
double-stranded AAV genome, thus eliminating the rate-limiting 
second strand synthesis for AAV transduction and enhancing 
transgene expression.28,29 hese features minimize the dose of vec-
tor required to achieve robust transduction and expression within 
liver tissues in vivo.
Our irst generation molecule, termed TT-033 (aka 
PF-0488818), possessed potent activity against HCV in a replicon 
model and demonstrated almost complete penetration of hepatic 
tissues following intravenous injection in nonhuman primates 
(NHPs). Yet liver toxicity was observed in a dose-dependent man-
ner, which we hypothesized was due to the strong transcriptional 
activity of each of the Pol III promoters and led to an overabun-
dance of shRNA. A simple reduction in the dose of vector admin-
istered led to incomplete transduction of hepatocytes, potentially 
leaving a reservoir of HCV positive cells for continued viral repli-
cation and infection of untransduced cells.
To test the hypothesis that too much shRNA caused toxicity, 
transcriptional activity was signiicantly reduced from each Pol 
III promoter in our second generation molecule, TT-034 (aka 
PF-05095808), by exchanging a less active U6-7 PSE regulatory 
element into each promoter. Despite measurably reduced levels of 
shRNA, the construct was nonetheless still efective at maintain-
ing eicient inhibition of the HCV replicon model. In vivo test-
ing demonstrated that the vector was capable transducing NHP 
hepatocytes at levels comparable to the TT-033, but was now 
devoid of hepatotoxicity. hus, re-engineering of the expression 
cassette has resulted in an agent that maintains eicacy and that is 
safe over a range of doses in a NHP model. hese data predict that 
the product will be safe and eicacious in clinical testing.
RESULTS
Individual shRNA sequences were designed to target highly con-
served HCV sequences from the (+) RNA genome across multiple 
genotypes (Figure 1a). Each shRNA was subcloned into an expres-
sion cassette comprised of three independent transcriptional 
cassettes under the control of three unique members of the U6 
promoter family.22 In order to verify RNAi activity of each shRNA, 
cells were cotransfected with the expression plasmid along with a 
reporter plasmid in which one of the targeted HCV sequences was 
fused downstream of the irely luciferase open-reading frame. 
Although the shRNA were designed to target sequences within 
the (+) RNA of HCV, the virus also uses a (–) strand RNA genome 
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Figure 1 In vitro anti-hepatitis C virus (HCV) inhibitory activity of 
short hairpin RNAs (shRNAs) against a HCV replicon model system. 
(a) Schematic illustration of the TT-033 vector and expression cassette 
demonstrating the presence of three independent transcription  cassettes, 
the order of the shRNA as well as the corresponding targeted regions 
and sequences within the HCV genome. A = U6-9 promoter; B = U6-1 
promoter; C = U6-8 promoter. (b) Inhibition of renilla luciferase enzy-
matic activity in a Huh7-based HCV replicon model in which the reporter 
gene has been fused into the RNA genome. Replicon-containing cells 
were transduced with the indicated multiplicity of infection (MOI) of 
Ad-TT-033 and renilla activity monitored for up to 15 days following 
transduction. Each data point represents an average of n = 8 wells of 
independently transduced cells. Percent inhibition was calculated as the 
amount of renilla activity as compared to untransduced wells of cells. 
Figure 1a is reprinted with permission. Copyright© American Society for 
Microbiology, Antimicrobial Agents and Chemotherapy (2012) 56:1364-
1375, doi: 10.1128/AAC.05357-11.
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intermediate during the replication cycle; in theory both strands 
of the RNAi duplex could be active. Testing revealed that while 
shRNA-6 cleaved both the (–) and (+) RNA of the HCV genome, 
shRNA-22 and shRNA-19 only eiciently cleaved the (+) strand 
(Supplementary Figure S1).
One of the principal limitations of testing the activity of 
shRNA expression plasmids against the HCV replicon system is 
that Huh-7 cells, the only known cell line that supports robust 
replicon activity, is recalcitrant to typical transfection methods. In 
addition, although AAV8 is highly tropic for liver tissues in vivo, 
it is very ineicient at transducing tissue culture cells. hus, to 
determine if the shRNA inhibited replicon activity, the expres-
sion cassette for TT-033 was subcloned into a transfer vector for 
production of recombinant adenovirus, known for broad tropism 
and eicient transduction of cells in vitro. Huh-7 cells harboring 
the HCV replicon were infected with diferent multiplicities of 
infection (MOIs) of Ad-TT-033 and the levels of replicon inhibi-
tion measured at various time points ater vector administration. 
he data demonstrated that HCV replicon activity can be inhib-
ited in a time- and dose-dependent manner (Figure 1b); a MOI 
of 11 was suicient to inhibit replicon activity by ~100% at day 15. 
Cells transduced with an adenovirus stock expressing GFP dem-
onstrated no appreciable changes in replicon activity at MOIs up 
to 100 (data not shown) indicating that the efect was speciic to 
expression of the shRNA and not a result of the adenovirus deliv-
ery vehicle.
Transduction and toxicity assessment of TT-033 
in Cynomolgus monkeys
A 50-day non-GLP dose range inding study with TT-033, a 
vector comprised of a self-complementary expression cassette 
(Figure 1) packaged in the serotype 8 AAV capsid, was con-
ducted by administering a single intravenous injection into 
13 Cynomolgus monkeys at doses ranging from 1.25 × 1011 to 
1.25 × 1013 vector genomes per kilogram body weight (vg/kg). 
Before dosing, serum samples from the animals were screened 
for the prevalence of neutralizing antibodies against AAV8 to 
prevent confounding efects that may potentially arise from an 
unintended immune clearance of the vector leading to a lack of 
eicient transduction. Animals with levels of pre-existing serum 
antibody titers against AAV8 that were >1:5 were excluded from 
the study. During the course of the experiment, blood was col-
lected weekly for clinical chemistry analysis in order to assess liver 
toxicity. Dose-dependent increases in alanine aminotransferase 
(ALT) (Figure 2a,b) were observed in NHPs administered 3.75 × 
1011 vg/kg or greater of TT-033. Other dose-dependent changes 
consistent with hepatic injury included elevations in aspartate 
aminotransferase and alkaline phosphatase as well as decreases 
in albumin and total cholesterol (Supplementary Figure S2a–d). 
he parameters changed from baseline levels starting on or ater 
day 21 post injection, peaked by day 36, and were trending toward 
resolution by day 50. One of the animals that received the highest 
dose of 1.25 × 1013 vg/kg was sacriiced at day 42 due to morbid-
ity, and on gross and histological examination was found to have 
liver injury characterized by marked bridging hepatic necrosis. 
hese serum chemistry data, which indicate hepatic damage, are 
consistent with results obtained in a 121-day acute toxicity study 
performed in female mice by administering a single intravenous 
injection of TT-033 ranging from 6.25 × 1010 to 1.25 × 1012 vg/
kg (Figure 2c and Supplementary Figure S3a–d). Consistent 
with previous AAV studies that demonstrate more rapid onset 
of transgene expression in rodents than NHPs,30 the progres-
sion of hepatocellular toxicity was faster in the murine model; 
the change in analogous parameters occurred as early as day 8, 
peaked at day 11, and resolved back to normal levels by day 31. 
A cohort of mice dosed with empty AAV8 capsids at protein lev-
els consistent with the TT-033 dose of 1.25 × 1012 vg/kg showed 
no signiicant changes in ALT levels from baseline values at day 
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Figure 2 Alanine aminotransferase (ALT) activity in Cynomolgus 
monkeys and mice dosed with TT-033. Serum was collected at vari-
ous time points following a single dose of TT-033 administered intrave-
nously to Cynomolgus monkeys into either the cephalic or saphenous 
vein at (a) low dose levels of 1.25 × 1011 vg/kg (blue diamonds, n = 2), 
3.75 × 1011 vg/kg (light green squares, n = 3) or 1.25 × 1012 vg/kg (red 
circles, n = 2) or (b) at high-dose levels of 3.75 × 1012 vg/kg (orange 
circles, n = 4) to 1.25 × 1013 vg/kg (green triangles, n = 2). ALT measure-
ments from individual animals are shown for each data point. For data in 
(a) and (b), individual data points are plotted for each monkey and are 
demarcated using study specific animal numbers (SSAN). For the murine 
study (c), TT-033 was injected intravenously into the tail vein at dose 
levels of 6.25 × 1010 vg/kg (orange diamonds), 1.25 × 1011 vg/kg (blue 
diamonds), 6.25 × 1011 vg/kg (red circles) and 1.25 × 1012 vg/kg (green 
triangles). Mice dosed with saline (black squares) served as the negative 
control. Murine serum was collected at terminal necropsy at each time 
point. The plotted data average and standard deviation at each point are 
based from N = 5 mice per dosing cohort.
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8 indicating that the capsid was not responsible for the hepatic 
toxicity (data not shown).
he NHP model showed a strong correlation between dose 
and the severity of liver lesions detected by histopathology 
(Supplementary Figure S4). Test article-related hepatic lesions 
consisted of irregular liver surfaces with prominent lobular mark-
ings on gross examination and apoptosis of hepatocytes, bile duct 
hyperplasia, deposition of brown pigment, Kupfer cell hyperpla-
sia, mitotic igures in liver cells, bridging necrosis, and hepatocel-
lular regeneration on the microscopic examination. In addition, 
the murine model demonstrated dose-independent indings in 
the adrenal glands with cortical degeneration and vacuolation 
as early as day 8, which persisted through day 30 but cleared by 
day 91. Similarly, a transient mineralization of blood vessels of the 
myocardium was noted in high-dose cohorts of mice sacriiced at 
day 11, but was reduced in frequency and severity at later time-
points and absent altogether by day 121. here were no clinical 
indings or mortality associated with these microscopic adrenal 
and cardiac indings. Signiicantly, neither adrenal vacuolation 
nor myocardium mineralization occurred at any dose in the NHP 
model.
In situ hybridization analysis (ISH) was performed using 
locked nucleic acid (LNA) probes that were able to qualitatively 
detect the presence of expressed shRNA within liver cells. ISH 
analysis of serial sections of day 30 hepatic tissue from SSAN3, 
dosed with 1.25 × 1012 vg/kg TT-033, reveals cytoplasmic staining 
and a uniform pattern of distribution of each of the shRNAs across 
nearly 100% of the hepatocytes whereas no staining is noted in 
the surrounding vascular wall and perivascular connective tissue 
within the hepatic parenchyma (Figure 3b,d, and f). No shRNA 
staining was noted in hepatic tissues from a saline treated animal 
(Figure 3a,c, and e). Quantitative measurements of vector trans-
duction and shRNA expression was assessed by quantitative PCR 
(QPCR) in liver biopsies collected at day 15 from the Cynomolgus 
monkeys and in livers harvested at the conclusion of the experi-
ment. Weaker probe binding appears to be the cause of lightly 
stained tissues in qualitative shRNA-22 ISH analysis (Figure 3) 
as QPCR measurements demonstrate equivalent expression of all 
three shRNA in SSAN3 (Figure 4c). Within individual animals, 
all three lobes of the liver sampled show equivalent levels of vector 
DNA as assessed by QPCR analysis, indicative of homogeneous 
distribution across the liver (Figure 4a).
Because recombinant AAV vectors are nonintegrating and 
maintained as episomes, previous studies demonstrate that hepa-
tocyte damage and regeneration oten results in the loss of vector 
from AAV-transduced cells.14 Indeed, although QPCR analysis 
of TT-033 DNA showed dose-dependent transduction of the 
liver in the day 15 biopsies, day 50 TT-033 levels were markedly 
decreased in animals that received high doses of the test article 
and experienced hepatocyte damage as indicated by the presence 
of elevated levels of liver enzymes (Figures 2a and Figure 4a). At 
low doses where hepatocellular toxicity was not observed, durable 
levels of transduction were sustained to day 50, the longest time 
point measured in these experiments. Within individual animals, 
QPCR analyses of shRNA demonstrate equivalent levels of all 
three hairpins being produced in hepatic tissues (Figure 4b,c). 
With the exception of the high-dose animals, the levels of shRNA 
measured within the biopsies are directly relective of the level of 
TT-033 DNA. Despite possessing exceptionally high numbers of 
TT-033 DNA copies/cell, the animals in the highest dose cohorts 
appeared to reach a threshold of shRNA expression. As vector is 
lost via hepatocyte damage and death, the ability to sustain high 
levels of transgene expression is also abrogated as evidenced by 
a concomitant decrease in shRNA levels in day 50 tissues. For 
example, in animals dosed with 3.75 × 1012 vg/kg (Figure 4a), day 
50 TT-033 DNA and shRNA levels were maintained at compa-
rable levels to day 15 biopsy samples in SSAN 5 and SSAN6. hese 
same animals showed negligible changes in ALT levels over that 
same time frame (Figure 2a). Conversely, copies of TT-033 DNA 
and shRNA measured at day 50 dropped from the levels detected 
in day 15 biopsies in SSAN14 and SSAN17 and were concomitant 
with signiicant elevations of ALT in those animals. hus, despite 
eicient and near complete transduction of hepatocytes, the loss 
of vector and increased hepatic enzyme levels in serum indicate 
that shRNA-mediated hepatic toxicity resulted from high doses 
of TT-033. Yet, simply reducing the amount of vector adminis-
tered (Figure 4a) resulted in incomplete hepatocyte transduction 
potentially leaving a subset of HCV-infected cells untreated and at 
risk for infecting other nontransduced normal hepatocytes.
Engineering promoters to eliminate toxicity
Given the dose-dependent toxicity indings, we hypothesized 
that lowering the transcriptional levels of shRNA expression per 
promoter could reduce toxicity while preserving the ability to use 
doses suicient to ensure complete transduction of hepatocytes. 
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Figure 3 Distribution and homogeneity of short hairpin RNA 
(shRNA) expression in serial liver sections from Cynomolgus mon-
keys dosed with TT-033. Representative in situ hybridization (ISH) 
analysis of shRNA expression levels in hepatocytes using locked nucleic 
acid (LNA)-based probes against the hairpin sequences against (a and b) 
shRNA-6, (c and d) shRNA-19 and (e and f) shRNA-22. Tissues for (a,c, 
and e,) were taken from SSAN1, a monkey administered saline as a neg-
ative control while (b,d, and f) came from serial liver sections of SSAN3, 
a monkey dosed with 1.25 × 1012 vg/kg of TT-033.
© The American Society of Gene & Cell Therapy
Anti-HCV shRNA in a Nonhuman Primate Model
Molecular herapy  vol. 20 no. 9 sep. 2012 1741
As activity of the U6-8 promoter was signiicantly reduced by 
replacing the wt PSE region with the corresponding PSE from 
U6-7,22 similar changes were engineered into the promoters of 
PF-0488818. he individual shRNA and all other components of 
the drug remained unchanged; this new molecule was labelled 
TT-034. RNAi activity from the hybrid promoters was tested 
by cotransfecting tissue culture cells with luciferase expression 
reporter constructs and plasmids encoding for individual shRNA 
transcribed by either hybrid or wt U6 promoters. Because even 
low levels of shRNA can lead to high levels of reporter inhibition, 
transfection conditions included a range of the shRNA expression 
plasmid. he percentage of luciferase reporter inhibition mediated 
by shRNA-6 expression from the wt U6-8 promoter remained rel-
atively unchanged despite titrating down the input plasmid from 
250 to 1 ng per transfected well (Figure 5a) Likewise, use of wt 
Pol III promoters to drive shRNA-19 (Figure 5b) and shRNA-22 
(Figure 5c) expression resulted in sustained inhibition until trans-
fected quantities are reduced to 10 ng per well or below. Conversely, 
even at 250 ng per well, reduced inhibition levels were measured 
in transfection mixtures using the plasmids containing the hybrid 
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Figure 4 Transduction and short hairpin RNA (shRNA) expression in hepatic cells from Cynomolgus monkeys dosed with TT-033. Hepatic tis-
sues were analyzed for either DNA or shRNA levels following intravenous administration of a single dose of TT-033 into either the cephalic or saphen-
ous vein at dose levels ranging from 1.25 × 1011 vg/kg to 1.25 × 1013 vg/kg. Samples of liver were collected from biopsies performed 15 days following 
vector dosing, or from tissues of the right, medial, or left lobe taken at necropsy of the specified day. Biopsies were not collected from monkeys with 
asterisks next to the animal identifier number. (a) Genomic DNA was purified from each sample and DNA copies of TT-033, a measure of transduc-
tion, was assessed by QPCR. Each data point represents an average analysis from four independent aliquots of each genomic DNA sample. Levels of 
DNA from biopsy material are shown in black while material sampled from the right, medial or left lobe are represented by the green, blue and red 
columns, respectively. (b and c) RNA was collected and purified individually from each of the samples and shRNA-22 (green), shRNA-19 (blue), or 
shRNA-6 (red) expression levels examined using QPCR procedures. For biopsy samples, the data represents analysis in triplicate from RNA extracted 
from the individual sample. For tissues collected at necropsy, each data point and associated standard deviation represents the combined average 
from the independent analysis of one RNA sample taken from each of the three lobes.
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Pol III promoters. More importantly, the ability to inhibit the 
reporter plasmid dropped far more quickly as the amount of the 
shRNA expression plasmid is decreased. For instance, ~70% inhi-
bition of the shRNA-22 luciferase reporter could be achieved by 
transfection of 100 ng of the plasmid containing the hybrid Pol III 
promoters, whereas only 5 ng of the corresponding plasmid with 
wt promoters was required to achieve the same level of inhibition: 
a 20-fold diference.
To prove the hypothesis that lowered RNAi activity results 
from decreased shRNA production with the hybrid promoters, 
shRNA-22 levels were measured in RNA harvested from paral-
lel wells using QPCR. Cells transfected with 100 ng of wt expres-
sion plasmid express an average of 43,710 copies/cell (Figure 5c). 
he same amount of transfected hybrid Pol III promoter plasmid 
yielded 16-fold less shRNA-22. Cells transfected with either 10 ng 
or 1 ng of the wt plasmid expressed 3,398 and 2,423 copies/cell, 
respectively, comparable to the level of shRNA-22 measured in 
cells transfected with 100 ng of the expression construct with the 
hybrid promoters.
Inhibition of a HCV replicon model with TT-034
As with the irst generation compound, an adenovirus variant of 
TT-034 was tested for the ability of the shRNA to inhibit HCV 
replicon activity. Huh-7 cells harboring the HCV replicon were 
infected with diferent MOIs of Ad-TT-034 and the levels of 
replicon inhibition measured at various time points ater vector 
administration. he data demonstrate that despite reduced shRNA 
expression, HCV replicon activity can be eiciently inhibited 
by TT-034 (Figure 6a). In order to quantify the amount of each 
shRNA required for inhibition of replicon activity, parallel wells 
of cells treated at identical conditions were harvested for RNA, 
and shRNA levels were measured by QPCR. Shown in Figure 6b, 
levels of each shRNA accumulate through day 3 and then drop 
of, likely because adenovirus is nonintegrating and is diluted 
out as cells divide. hough, we are taking static measurements of 
shRNA to measure the dynamic process of replicon inhibition, 
the results from these experiments, particularly cells treated with 
an MOI as little as 30, suggest that between 20 and 220 copies of 
each shRNA per cell may be suicient to abrogate replicon activity 
(Figure 6b).
Transduction and toxicity assessment of TT-034 
in Cynomolgus monkeys
A follow-up 50-day, non-GLP Cynomolgus monkey study was 
then performed on 18 NHPs to assess transduction and toxicity 
ater a single intravenous administration of the modiied com-
pound TT-034. A parallel cohort of six NHPs was dosed with the 
irst generation compound, TT-033, in order to assess any difer-
ences in transduction eiciency and shRNA expression through 
day 15. Following administration of TT-034, a mild elevation in 
serum ALT and aspartate aminotransferase was noted to occur at 
day 4 in high-dose animals (Figure 7a and Supplementary Figure 
S5a). his transient increase resolved to baseline levels by day 11. 
Because the previous onset of liver enzyme increases in response 
to TT-033 did not occur until ater day 20 (Figure 2a,b), it is likely 
that the transient day 4 response in this animal is unrelated to 
the expression of the shRNA. More importantly, and unlike the 
Figure 5 Changes in short hairpin RNA (shRNA) expression and 
inhibitory activity from constructs with modified Pol III promot-
ers. The activity of individual shRNA from expression plasmids coding 
for (a) shRNA-6, (b) shRNA-19, or (c) shRNA-22 that are driven from 
either wt Pol III promoters (black) or modified promoters (gray) were 
tested against their cognate luciferase reporter constructs. A Renilla 
expression plasmid was also included in each transfection mixture 
to normalize for differences in transfection efficiency. A nonspecific 
plasmid DNA was used to normalize the amount of nucleic acids 
used for each transfected condition. The percent inhibition was cal-
culated by comparison of luciferase activity in cells transfected with 
an identical reporter and a U6-1 plasmid lacking an expressed shRNA 
sequence. Each analysis represents data collected from four replicate 
 transfections ± SD.
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irst generation drug TT-033 which demonstrated dose-depen-
dent shRNA related liver injury at doses of 3.75 × 1011 vg/kg or 
above, all remaining animals in the TT-034 cohorts showed no 
changes in markers of hepatic injury throughout the course of the 
experiment, despite being dosed with TT-034 at concentrations as 
high as 6.25 × 1012 vg/kg (Figure 7a and Supplementary Figure 
S5b–d). here were also no microscopic changes found by his-
topathology analysis in the liver that were related to the admin-
istration of TT-034. he lack of toxicity as a result of TT-034 
administration was conirmed by a parallel 30-day acute toxicity 
study performed in a murine model. Despite signiicant changes 
in liver function tests in animals dosed with TT-033 at 6.25 × 1011 
vg/kg or higher (Figure 2c and Supplementary Figure S3a–d), 
mice dosed with the second generation compound at levels up to 
1.25 × 1013 vg/kg, 50-fold higher, showed no changes in any liver 
function test parameters as compared to saline control (Figure 7b 
and Supplementary Figure 6a,b).
Because the composition of the viral capsid, the primary 
determinant of transduction, remains unchanged between the two 
molecules, it was predicted that equivalent doses would result in 
a similar number of DNA copies of the respective vectors per cell. 
Indeed, although the doses of test article were slightly diferent, the 
day 15 TT-033 (Figure 8a) and day 15 TT-034 (Figure 8b) liver 
transduction levels were within two-fold of one another. However, 
QPCR analysis of shRNA levels demonstrated a marked reduc-
tion in levels of shRNA expressed from TT-034-transduced cells 
as compared to their TT-033 counterparts, a inding anticipated 
based on the manipulation of the U6 promoters (Figure 8d-f). For 
instance, day 15 animals dosed with 1.25 × 1012 vg/kg of TT-033 
produced, on average, 52,358 copies of shRNA-22 per cell, 68,724 
of shRNA-19 per cell, and 60,809 copies of shRNA-6 per cell; while 
a corresponding dose of 1 × 1012 vg/kg TT-034 produced 1,223, 
196, and 782 copies/cell, respectively. Because shRNA-mediated 
toxicity has been eliminated, the levels of TT-034 DNA are largely 
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maintained through day 50 with a slight decrease across the 
same dosing cohorts from day 15 (Figure 8b versus Figure 8c). 
In addition, QPCR analysis demonstrates similar shRNA levels 
between comparably dosed animals at day 15 and 50 (Figure 8e 
versus Figure 8f), reairming that no hepatocellular toxicity has 
occurred and demonstrates that steady state levels of shRNA are 
likely attained at the earlier timepoint.
DISCUSSION
Even with the recent introduction of oral HCV protease inhibitors,2,3 
and associated sustained virologic responses of up to 75% in com-
bination with interferon/ribavirin, HCV-infected patients still face 
a prolonged course of treatment with considerable side-efects.31 
he development of an efective shRNA approach could provide a 
therapeutic option that requires only a single injection, is devoid of 
the debilitating side-efects associated with current treatment regi-
mens and has the potential to help provide beneit to patients with 
viral pools refractory to current treatment options. Alternatively, a 
shRNA approach could be used in combination therapies to mark-
edly reduce the number of HCV-infected cells in the liver and allow 
for more eicient use of the current clinical drugs.
Treatment of infectious diseases by RNAi-based therapeu-
tics provides an especially diicult challenge considering that the 
mechanism of action is dependent upon sequence speciicity and 
that the replication machinery employed by many viruses gener-
ates a large pool of heterogeneous genomes. Fatefully positioned 
mutations within target sequences could quickly abrogate the 
inhibitory activity of a single RNAi inhibitor and give rise to a 
nonresponding virion subpopulation. Each of the shRNA in 
TT-034 was carefully chosen to inhibit a diferent, well-conserved 
area of the HCV genome and, much like the combination of small 
molecule drugs used in the treatment of HIV with highly active 
antiretroviral therapy, simultaneous expression of the shRNA 
thus provides a pool of therapeutic sequences that target mul-
tiple regions of the HCV genome simultaneously, thereby creat-
ing a “cocktail in one drug.” A more detailed report describing 
the activity of TT-034 against the most abundant individual point 
mutations found in the clinic and HCV replicon variants other 
than genotype 1 has recently been published.32
Given that HCV infects an ever-changing subset of hepato-
cytes within a human liver, infection is focal and likely transient 
in the liver33 and variable between patients,34 a key require-
ment for an antiviral RNAi therapeutic to be curative would be 
the ability to transduce a high proportion of the hepatocytes. 
Failure to do so might permit untransduced, HCV-infected cells 
to continue shedding virus and potentially leaves uninfected 
cells at risk and vulnerable to nascent infection. hus, a deliv-
ery method must be used that eiciently transduces nearly all 
hepatocytes, hence our choice of AAV8. Biodistribution analy-
sis of over 30 diferent tissues from the cynomolgus monkeys 
dosed with TT-033 demonstrates that nearly 90% of AAV8 vec-
tor administered localizes to the hepatic tissues (data not shown, 
additional manuscript in preparation). Furthermore, transduc-
tion must be accomplished from a single administration of 
the therapeutic, as repeat dosing is untenable because of the 
humoral immune response which is generated by the memory 
B cells in response to the large infusion of viral capsids. Figures 
3 and 4a and demonstrate that transduction of TT-033 is near 
homogeneous across hepatic tissues from a single administra-
tion of the drug.
Our work demonstrates that when suicient doses of vector 
were used to ensure broad transduction of hepatocytes, wt Pol III 
promoters drive transcription of the shRNA at suiciently high 
levels to cause hepatocellular toxicity in both murine and NHP 
models. To our knowledge, this is the irst description of shRNA-
mediated toxicity shown to occur in NHPs and argues this toxicity 
may well be conserved in humans. Previous studies have suggested 
that shRNA-mediated saturation of Exportin-5, an essential com-
ponent of the endogenous RNAi cellular machinery responsible 
for translocation of miRNA from the nucleus to the cytoplasm, 
can lead to a global dysregulation of endogenous miRNA process-
ing and perhaps account for liver toxicity.14 While the experiments 
presented here do not deinitively identify the speciic mechanism 
of shRNA-mediated toxicity, a parallel TT-033 study (data not 
shown) in a murine model demonstrated that a large proportion 
of mature miRNA levels are not perturbed by TT-033 induced 
hepatocellular toxicity thus suggests that the shRNA had not 
induced toxicity by saturation of Exportin-5. Regardless, a strat-
egy was required to keep the level of AAV8 vector administered 
at suiciently high levels to maximize hepatocyte coverage while 
concomitantly reducing the cellular toxicity from the expressed 
shRNA. Several diferent approaches have been described that 
alleviate toxicity due to overexpression of shRNA. For example, 
shRNA directed against the mRNA sequences for the mutant 
huntingtin protein have been modeled into miRNA backbones, 
resulting in reduced striatal toxicity, but no compromise of the 
RNAi activity of the sequence. his corrective efect was attributed 
to a lowering of overall levels of mature shRNA species in which 
the hairpins associated with the precursor have been cleaved.15,16 
In the current study, engineering minor changes into the regu-
latory promoter elements of all three promoters to reduce tran-
scriptional levels obviated the need to redesign shRNA sequences 
or use a delivery vehicle other than AAV8, a highly hepatotropic 
serotype. he resulting vector, TT-034, expresses the same three 
shRNA sequences at signiicantly reduced levels compared to 
TT-033, thus allowing the use of high levels of vector to transduce 
Figure 8 Transduction and short hairpin RNA (shRNA) expression in hepatic cells from Cynomolgus monkeys dosed with TT-033 or TT-034. 
Cohorts of Cynomolgus monkeys were injected with either (a) TT-033 at doses of 1 × 1011, 1 × 1012, or 5 × 1012 vg/kg on day 0 or (b,c) TT-034 at 
doses of 1.25 × 1011, 1.25 × 1012, or 6.25 × 1012 vg/kg on day 0 and then sacrificed on either (a, b) day 15 or (c) day 50. Hepatic tissues from the 
left lobe (black columns), medial lobe (light gray), or right lobe (dark gray) were harvested at necropsy. Genomic DNA was collected and purified 
from the livers of each of the animals and was measured for transduction using QPCR procedures. Each analysis represents data collected from three 
aliquots of the genomic DNA samples. Sample from animal number 4 (c) resulted in 0.6, 0.8, and 0.9 DNA copies per hepatocyte from the left, 
medial, and right lobes, respectively. (d,e,f) RNA was collected and purified individually and shRNA-22 (green), shRNA-19 (blue), or shRNA-6 (red) 
expression levels examined using QPCR procedures. Each bar and associated SD represents the combined average from the independent analysis of 
one RNA sample taken from each of the three lobes.
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a large percentage of hepatocytes, without associated shRNA tox-
icity. he reduction of shRNA levels from the modiied U6 pro-
moters was demonstrated on an activity level from a luciferase 
reporter system (Figure 5) as well as physically shown by QPCR 
analysis of liver tissues from NHPs (Figure 8d–f).
he results of in vitro replicon experiments demonstrated 
potent anti-HCV activity of each of the shRNA expression con-
structs. he ability to approximate the levels of shRNA required 
to inhibit HCV replicon activity, as well as quantify the level of 
shRNAs produced in NHPs, suggest that clinically feasible doses 
of TT-034 administered to patients should be suicient to confer 
therapeutic beneit. Yet, the numbers of shRNA species required 
for inhibition of HCV on a per cell basis may actually be even lower 
than suggested by the transient replicon experiments (Figure 6); 
the adenovirus shRNA expression vector delivered to replicon 
containing cells is nonintegrating and thus was diluted amongst 
daughter cells as a result of cell division while in cell culture. he 
ability to use a shRNA approach with a vector which confers long-
term expression in vivo results in durable expression; indeed, data 
from our unpublished IND enabling studies demonstrates per-
sistent shRNA levels out to 180 days, the duration of the experi-
ments in the murine and Cynomolgus models (data not shown). 
Furthermore, it is important to note that while the replicons pro-
duce hundreds or thousands of copies of the HCV genome per 
cell35,36 chronically infected human hepatocytes harbor only 5–7 
copies/cell on average.33,37 Finally, the process of RNAi is catalytic; 
one active species loaded into the RNA-induced silencing com-
plex can result in multiple rounds of degradation.
Testing the ability to knock down HCV infection in vivo in a rel-
evant NHP model system remains an ongoing challenge, as the only 
species other than man that supports reliable viral replication is the 
chimpanzee. Due to the inability to perform extensive toxicology 
and histopathology on chimpanzees, the replicon continues to be 
the industry accepted model for anti-HCV activity. Murine models 
in which chimeric livers comprised in part of human hepatocytes 
can support replication of HCV in vivo but are exceptional fragile, 
limiting the ability to produce large numbers of viable animals and 
results in substantial variability.38 In summary, we have shown that 
complete transduction of hepatocytes with TT-034 in a NHP, at lev-
els that yield 100% inhibition in the replicon models. hese doses 
of the modiied vector, which can be delivered by a single injection, 
were not associated with toxicity in either mice or NHPs. hese data 
justify the progression of this molecule to the clinic for the treat-
ment of chronically infected HCV patients.
MATERIALS AND METHODS
Selection of targetable sequences from (+) strand of the HCV genome. 
HCV genotypes difer by as much as 31–34% in their nucleotide sequences, 
whereas subtypes (species within a given genotype) may difer by 20–23% 
based on full-length genomic sequence comparisons. hus, regions of the 
viral genome with a high degree of conservation must be identiied and 
carefully chosen to ensure that the clinical candidate will cast the broadest 
therapeutic net possible. To select shRNA sequences, a Jotun Hein bio-
informatics alignment using MegAlign sotware (DNAStar) of all pub-
lished independent full-length or near-full-length HCV sequences in the 
Lawrence Livermore database was performed (http://hcv.lanl.gov/content/
index). In October 2003, when the analysis was initially performed, there 
were ~100 such sequences populated in that speciic database. Although 
the distribution of sequences was skewed toward genotype 1 viruses, 
sequences representing genotypes 1 through 6 were analyzed. In the most 
optimal case, there would be a minimum of 21 nucleotides (nt) which 
would maintain absolute identity across all species analyzed for alignment. 
In the absence of having conservation of absolute identity, the stringency 
may be reduced to 80% of all sequences tested. he G/C base content must 
fall within a 35–65% range. he selected sequences must have a general 
lack of cross speciicity to endogenous human targets (non-HCV) when 
queried against sequence databases.
Cynomolgus studies. Male and female Cynomolgus monkeys (Macaca 
fascicularis) were obtained and housed at SNBL USA (Everett, WA). SNBL 
USA is accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC), has an Animal Welfare Assurance 
issued by the Oice of Laboratory Animal Welfare (OLAW), is registered 
with the United States Department of Agriculture (USDA), and has an 
Institutional Animal Care and Use Committee (IACUC) responsible for 
SNBL USA’s compliance with applicable laws and regulations concerning 
the humane care and use of laboratory animals. Before the studies, the ani-
mals were given rigorous physical examinations and evaluated for clinical 
pathology parameters. Test article was administered intravenously ater 
being diluted to the appropriate dose concentration with a solution con-
sisting of 180 mmol/l sodium chloride, 10 mmol/l sodium phosphate, and 
0.001% Poloxamer, pH 7.3. Intravenous bolus injection using an integrated 
straight needle was followed by a 2-ml lush with diluent. Serum chemistry 
analysis was performed on an Olympus AU640 analyzer. During necropsy, 
liver specimens were harvested, snapped frozen in liquid nitrogen and 
shipped to Tacere for analysis of DNA and shRNA levels. For histopathol-
ogy analysis, a variety of tissues were collected, trimmed, placed in cas-
settes and ixed for 24 ± 2 hours in 4% paraformaldehyde at 2–8 °C prior to 
further processing. One set of perfused tissues was processed into parain 
blocks. he second set of tissues was immersed in 0.5 mol/l sucrose diluted 
in TBS for 48 hours at 2–8 °C, then mounted in OCT and frozen. OCT-
mounted tissues were stored at –60 °C until observation by the pathologist 
for histopathology.
Mouse studies. Murine studies for animals dosed with TT-033 were con-
ducted at Covance Laboratories (Harrogate, UK). he study was con-
ducted in accordance with the requirements of the Animals (Scientiic 
Procedures) Act 1986 (UK). Mice of the Crl: CD-1 (ICR) strain were 
obtained from Charles River UK Limited (Margate, UK). Murine studies 
for TT-034 were performed on male CD-1 mice at Pizer (Andover, MA) 
and the study was conducted in accordance with the In Vivo Guidelines 
of Pizer Global Research & Development (St Louis, MO). Test article was 
administered intravenously ater being diluted to the appropriate dose 
concentration with a solution consisting of 180 mmol/l sodium chloride, 
10 mmol/l sodium phosphate, and 0.001% Poloxamer, pH 7.3. For both 
studies, up to 200 µl was the maximal volume given by lateral caudal tail 
vein injection. Serum chemistry analysis was performed on samples col-
lected at each necropsy point. During necropsy, liver specimens were har-
vested, snapped frozen in liquid nitrogen for analysis of DNA and shRNA 
levels.
Neutralizing antibody screening. Cynomolgus monkeys were pre-
screened for the presence of neutralizing antibodies, high titers of which 
have the potential to limit transduction. Animals in the TT-033 dose range 
inding study were screened using an AAV8 reporter virus (Children’s 
Hospital of Philadelphia) that expressed the β-lactamase gene as previously 
described.39 For experiments performed with TT-034, serum samples were 
screened with a modiied protocol that used an AAV8 reporter vector that 
delivered the sequences encoding for luciferase (Virovek, Hayward, CA).
TT-033 plasmid construction. he pSiren Shuttle plasmid (Takara 
Biosciences-Clontech, Mountain View, CA), which contains the U6-1 wt 
promoter, was used for expression of single short hairpin molecules. Target 
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sequences of 19 nt for shRNA-19 were synthesized as duplex primer pairs 
with ends that are compatible with the 5′ BamHI and 3′EcoRI restriction 
sites available in the pSsh expression vector. When the irst nucleotide of 
the guide strand to be produced was a pyrimidine, a purine was added, 
as the transcription complex that uses the U6 promoter prefers to initi-
ate on this nucleotide. Two U6 related promoters, U6-8 and U6-9, were 
identiied whose promoter activity was equal to U6-1 in an in vitro tran-
scription assay.22 Each promoter was synthesized in a PCR and individually 
cloned into a derivative of the U6-1 expression vector resulting in pU6-8 
and pU6-9 expression vectors. A plasmid containing all three Pol III pro-
moters, in the order U6-9, U6-1, U6-8, was constructed with two stretches 
of 400 base pairs of the hypoxanthine-guanine phosphoribosyltransferase 
gene (HPRT) intron 1 to provide spacer sequences between the three 
promoters. In order to generate stufer sequences, an 800 base pair frag-
ment, corresponding to a portion of the intron 1 sequence of the HPRT, 
was isolated using PCR ampliication and anchored PCR used to split the 
ampliied fragment into two equivalently sized stufers. Similar regions 
from HPRT have been used for stufer fragments on other recombinant 
viral vectors.40 Each promoter has unique enzyme sites for rapid insertion 
of shRNAs. hree speciic shRNA-coding DNA duplexes were inserted 
behind each promoter. Long-DNA oligonucleotide primers were annealed 
and cloned sequentially into the vector. Primer sequences for each of the 
three hairpins consisted of:
shRNA-6 top: 5′-GATCCCGCGAAAGGCCTTGTGGTACTGAAGC
TTGAGTACCACAAGGCCTTTCGCTTTTTTCTAGAGAATTCTG-3′
shRNA-6 bottom 5′-CAGAATTCTCTAGAAAAAAGCGAAAGG
CCTTGTGGTACTCAAGCTTCAGTACCACAAGGCCTTTCGCGGG
ATC-3′
shRNA-19 Top: 5′-CGAGGATCCGTCAACTCCTGGCTAGGCAAT
TTGTGTAGTTGCCTAGCCAGGAGTTGACTTTTTTCTAGAGAA-3′
shRNA bottom 5′- TTCTCTAGAAAAAAGTCAACTCCTGGCTA 
GGCAACTACACAAATTGCCTAGCCAGGAGTTGACGGATCC 
TCG-3′
shRNA-22 Top 5′- ACACTAGTATTGGAGTGAGTTTAAGC 
TGAAGCTTGAGCTTAAACTCACTCCAATTTTTTTAGATCTGT 3′
shRNA-22 bottom 5′- ACAGATCTAAAAAAATTGGAGTGAGTTT 
AAGCTCAAGCTTCAGCTTAAACTCACTCCAATACTAGTGT 3′.
he entire expression cassette was designed to have lanking sequences 
for insertion into inverted terminal repeat (ITR)-containing vectors for 
AAV production. For generation of self-complementary vectors used 
in the construction of this speciic product, the wt AAV2 right ITR was 
coupled with a nonresolvable let ITR from AAV4, which was commercially 
synthesized within the context of a pUC vector. he intervening sequences 
between the two ITRs was bounded by NotI restriction enzyme sites for easy 
removal and replacement with TT-033 expression cassette.
Modification of plasmid to create TT-034. Pairs of long oligonucle-
otides were synthesized that contained the PSE sequences from the 
U6-7 promoter. he termini of the hybridized PSE-7 sequences to be 
inserted into the U6-1 promoter were designed to have overhangs com-
plementary with NdeI and BamHI cleaved sequences. Likewise, BstEII 
and BamHI compatible overhangs were designed for PSE-7 hybridized 
primer pairs that were to be inserted into the U6-8 promoter. Following 
ligation, the modiied plasmids were sequenced to verify that the PSE-7 
sequence had been properly inserted. Because there were no convenient 
internal restriction sites to generate a PSE-7 exchange into the U6-9 pro-
moter, the entire promoter (including TATA box) was generated using 
oligonucleotide primer stitching via PCR. All clones were sequence veri-
ied and it was discovered that sequences downstream from the PSE-7 
sequences within the U6-9 promoter did not correspond to the endog-
enous U6-9 promoter. Instead, a design error had led to these sequences 
being replaced with the endogenous U6-8 sequences. Encompassing 
nearly 50 nt, and including the TATA box of the promoter, this hybrid 
promoter nonetheless remains active with the desired properties of 
reduced transcription levels and thus the sequence was not changed in 
future iterations.
Luciferase reporters: he vector pGL3-CTRL (Promega, Madison, WI.) was 
used for the construction of the irely luciferase fusion reporter plasmids. 
his vector has an XbaI site and an FseI site between 2 and 22 nt down-
stream, respectively of the translational stop codon of the luciferase coding 
sequence, convenient for ligating duplex primer pairs encoding for HCV tar-
get sequences on the same strand that transcribes the luciferase reporter.
Adenovirus production. Replication-deicient adenoviral vectors (E1/
E3 deleted) were produced at Vector Biolabs (Philadelphia, PA). Briely, 
the expression cassette for either TT-033 or TT-034 was subcloned into a 
shuttle vector and then homologous recombination was used to generate 
the recombinant viral vector. Primary stocks were ampliied in HEK293 
cell monolayers; cells were harvested and lysed and the virus puriied using 
two sequential cesium chloride gradients. he inal product was desalted, 
titered both spectrophotometrically for viral particles and plaque forma-
tion assay for PFU/IFU, and tested for sterility.
AAV production. he AAV helper free system (Stratagene, San Diego, CA) 
was used for construction of AAV-derived vectors and production of the 
AAV virus. he plasmid pAAV-RC from this system encodes the AAV2 
capsid protein and was modiied for production of AAV8 pseudotyped vec-
tors. he complete sequence of AAV8 was obtained from the NCBI data-
base (accession number AF513852). he capsid portion of the sequence 
was synthesized (Blue Heron Technologies, Bothell, WA) and directionally 
cloned into the pAAV-RC vector. Self-complementary AAV8 vectors were 
generated by modifying pAAV-MC from the Stratagene system by exchang-
ing the wt AAV2 ITR at the 5′ end of the plasmid with a mutant ITR from 
AAV4. he wt AAV2 ITR from the 3′ end of the vector plasmid remained 
unchanged. Recombinant AAV was generated by transient transfection 
of HEK293 cells, and puriied by combined column chromatography and 
cesium chloride gradient centrifugation as has been previously described,41 
however with the modiication that Poros 50HQ resin (Invitrogen, Carlsbad, 
CA) was used for the chromatography step. he puriied vector was essen-
tially free of empty capsids. Vector preps were titered by QPCR and titers 
were expressed in terms of vector genomes/ml (vg/ml). he QPCR primers 
used for titering were: Forward: 5′-AGCTCCACCCTCACTGGTTTTT-3′ 
Reverse: 5′- CAAGCATGATCAGAACGGTTGA -3′ and Probe: 5′-FAM- 
TTGTTGAACCGGCCAAGCTGCTG-TAMRA-3′ (Applied Biosystems, 
Foster City, CA). Serial dilutions of a linearized DNA plasmid encoding 
for the expression cassette of TT-034 was used as a standard for absolute 
quantiication.
Determination of AAV copy numbers (transduction of hepatic  tissues). 
Genomic DNA was isolated using the QIAamp kit (Qiagen, Valencia, 
CA) and the resultant quantiication of nucleic acids was performed 
using the PicoGreen dsDNA quantitation assay (Invitrogen). AAV vec-
tor genome copy number was determined from 0.5 -50 ng of genomic 
DNA using quantitative real-time PCR with a forward and reverse 
primer that sit on the boundaries of the HPRT stufer region and U6-8 
promoter region, respectively and a probe that spanned the junction of 
these two elements. he QPCR primers used for biodistribution studies 
were: Forward: 5′-TAAGGGCAGGGAATTGATCTAGAA-3′ Reverse: 
5′-GGGCACCCTGGGTAAAGG-3′ Probe: 5′-FAM-AAGCTAGTGGT 
ACCGGTCCTACGCGG-TAMRA-3′ (Applied Biosystems). Because the 
sequences within the amplicon did not change between the two expression 
cassettes, the same primer/probe set was used to quantify copies of TT-033 
and TT-034. Primers/probes were validated to ensure no cross reactivity 
to genomic DNA sequences from mouse and non human primate species. 
Serial dilutions of a linearized DNA plasmid encoding for the expression 
cassette was used as a standard for absolute quantiication.
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Determination of shRNA copy numbers. RNA was puriied from tissues 
using a modiied procedure with Trizol (Invitrogen). he protocol was fol-
lowed as outlined by the manufacturer with the exception that the concen-
tration of magnesium is adjusted to 111 mmol/l by the addition of MgCl
2
 
prior to the inal precipitation step. Custom QPCR assays were developed 
for each of the hairpins used in this study. Based upon established design 
rules42,43 the miRNA loop assay was altered using the Applied Biosystems 
Custom Taqman Small RNA assays with speciicity tailored to shRNA-22. 
Forty ive nanogram of total RNA from each liver sample was utilized for 
the reverse transcription reaction which was performed with idenitcal con-
ditions to the miRNA detection assay and a portion of the products used 
for the subsequent QPCR assay. Mature RNAi species for shRNA-6 and 
shRNA-19 were measured using a custom variation of the Mircury assay 
developed by Exiqon (Woburn, MA). A standard curve was generated 
for each species (i.e., 19 nt, 20 nt, etc.) utilizing a dilution series of puri-
ied RNA templates speciic for the corresponding assay. A portion of the 
reverse transcribed products were used in the subsequent QPCR assay.
Cell lines and transfections. HEK293 cells were seeded in 12-well tissue cul-
ture plates at 8 × 104 cells/well on the day before transfection. Transfections 
with shRNA expression plasmids and luciferase reporter plasmids were 
performed using Turbofect transfection reagent (Fermentas, Glen Burnie, 
MD) according to the manufacturer’s instructions. Each condition was 
tested with N = 4 independent transfections unless otherwise speciied. 
For experiments using irely luciferase fusion reporter plasmids, 250 ng/
well of the reporter plasmid and 150 ng/well of shRNA expression plasmid 
were added into the mixture along with 25 ng/well of a renilla expression 
plasmid pRL-SV40 (Promega); the latter used to normalize for diferences 
in transfection eiciency. Ater a 48-hour incubation period, cells were 
harvested and assayed for dual luciferase activity (Promega). For repli-
con experiments, Huh-7.5 cells (licensed from Apath LLC, St Louis, MO) 
were propagated in Dulbecco’s modiied Eagle’s medium supplemented 
with 10% fetal calf serum, 1 mmol/l sodium pyruvate, 1× nonessential 
amino acids, and 1× penicillin/streptomycin. he Huh-7-derived cell line 
supports replication of subgenomic RNA from the con1 strain of HCV 
genotype 1b, which is engineered to encode the irely luciferase reporter 
gene and neomycin phosphotransferase gene (licensed from RebLikon, 
Schriesheim, Germany). Replicon 1b cells were maintained in Huh-7.5 
medium supplemented with G418 at 500 µg/ml. Luciferase activity was 
measured using the Britelite assay system (Perkin Elmer, Waltham, MA) 
for Firely luciferase and the Renilla luciferase assay system (Promega) for 
Renilla activity.
In situ hybridization. Exiqon’s miRCURY LNA microRNA ISH Optimi-
zation Kit (FFPE), v1.3 was used for in situ analysis of all three hairpins 
delivered by TT-033. Parain embedded Cynomolgus liver sections were 
cut at 6 µm and mounted on clean, positively charged slides, allowed to air 
dry for 2 hours and placed at 4 °C overnight, then baked at 60 °C for 45 min-
utes the night before the experiment. Slides were deparainized with three 
5-minute immersions in Xylene, followed by subsequent ethanol (ETOH) 
baths: three times with 100% ETOH, two times with 95%, two times with 
70% and then rinsed once with PBS. he tissue was digested with Proteinase 
K (300 µl/slide) at a inal concentration of 15 µg/ml in Proteinase K bufer 
[5 mmol/l Tris–HCl (pH 7.4), 1 mmol/l EDTA, 1 mmol/l NaCl] for 10 min-
utes at 37 °C in a slide hybridizer. he Proteinase K reaction was stopped 
with two holds of PBS-T and slides were dehydrated in new alcohol baths: 
two times with 70% ETOH, two times with 95%, and three times with 
100% ETOH. Slides were air-dried on clean paper towel in the hood for ~15 
minutes. DIG-labeled LNA probes were denatured at 90 °C for 4 minutes, 
then snap chilled on an ice bath and added to 1× Hybridization bufer. he 
following ISH probes, double DIG-labeled and enhanced with LNA, were 
used: shRNA-22: 5′-DIG-agcttaaactcactccaat-DIG-3′; shRNA-19: 5′-DIG-
gtcaactcctggctaggcaa-DIG-3′; shRNA-6: 5′-DIG-gcgaaaggccttgtggtact-
DIG-3′. Slides were incubated with 25–50 µl of LNA double-DIG labeled 
probe at a inal concentration of 40–60 nmol/l for 1 hour at 57 °C. he slides 
were then washed in 5-minute increments with one wash of in 5× SSC, 
twice in 1× SSC, and twice with 0.2× SSC at the hybridization temperature, 
and then once with 0.2× SSC at room temperature, and then washed once 
with PBS-T. Tissue sections were then incubated in blocking bufer, DIG 
Wash and Block Bufer Set (Roche, Indianapolis, IN) for 15 minutes. Sheep 
anti-DIG-AP was added at 1:500, diluted in blocking bufer and 0.2% 
sheep serum, and incubated for 60 minutes. Slides were then washed three 
times with PBS-T and then incubated with NBT/BCIP substrate (Roche) 
in AP bufer (100 mmol/l Tris–HCl, 100 mmol/l NaCl, 5 mmol/l MgCl
2
, 
0.05% Tween-20, pH 9.5) containing 0.2 mmol/l Levamisole, for 2 hours 
in a humidifying chamber at 30 °C. he alkaline phosphatase reaction 
was stopped using KTBT bufer (50 mmol/l Tris–HCl, 150 mmol/l NaCl, 
10 mmol/l KCl), 2 × 5 minutes. Following two 5-minute washes with water 
and dehydration protocol with two immersions in 70% ETOH, two with 
95% and three times with 100%, coverslips were added to the slides with 
Eukitt mounting medium (Electron Microscopy Sciences, Hatield, PA).
SUPPLEMENTARY MATERIAL
Figure S1. In vitro anti-HCV inhibitory activity of shRNAs against a 
surrogate model system.
Figure S2. AST, ALP, albumin, and cholesterol activity in Cynomolgus 
monkeys dosed with TT-033.
Figure S3. AST, ALP, albumin, and cholesterol activity in mice dosed 
with TT-033.
Figure S4. Histopathology of liver tissues from Cynomolgus mon-
keys treated with TT-033.
Figure S5. AST, ALP, albumin, and cholesterol activity in Cynomolgus 
monkeys dosed with TT-034.
Figure S6. AST and ALP in mice dosed with TT-034.
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